RecruitingPhase 2NCT07489534

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daihong Liu
Intervention
PD-1Ab21-BCMA CAR-T cell immunotherapy(drug)
Enrollment
25 enrolled
Eligibility
14 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07489534 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials